Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Use of the Olleyes ETS Virtual Reality Platform in Screening for Abnormalities in the Ophthalmic Workup
Author Affiliations & Notes
  • Shu Feng
    Ophthalmology, University of Washington School of Medicine, Seattle, Washington, United States
  • Aashka Damani
    Ophthalmology, University of Washington School of Medicine, Seattle, Washington, United States
  • Andrew Chen
    Ophthalmology, University of Washington School of Medicine, Seattle, Washington, United States
  • Jennifer Yu
    Ophthalmology, University of Washington School of Medicine, Seattle, Washington, United States
  • Footnotes
    Commercial Relationships   Shu Feng None; Aashka Damani None; Andrew Chen None; Jennifer Yu None
  • Footnotes
    Support  Latham Vision Research Innovation Award, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6428. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shu Feng, Aashka Damani, Andrew Chen, Jennifer Yu; Use of the Olleyes ETS Virtual Reality Platform in Screening for Abnormalities in the Ophthalmic Workup. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6428.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Virtual reality (VR) devices with pupil tracking technology now allow for the assessment of multiple components of the ophthalmic workup, but it is unclear how VR testing compares with the clinical exam. We aim to determine the utility of the Olleyes ETS VR Platform (Olleyes, Inc.; Summit, NJ) for screening abnormalities in visual acuity, extraocular motility, pupillometry testing, and visual field by confrontation.

Methods : Subjects were recruited from the Eye Clinic at the University of Washington Medical Center in August 2023 and underwent ophthalmic workup by a trained ophthalmic professional (clinical exam) and by the VR platform. The VR testing bundle included visual acuity by tumbling E, extraocular motility (EOM) testing, visual field by confrontation, and a pupil (fast) exam. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for abnormal visual acuity (worse than 20/40), EOM deficit, presence of an afferent pupillary defect (APD), and deficit on visual field by confrontation on the VR platform compared to the clinical exam.

Results : Data was acquired from 80 eyes of 40 patients, 22 female and 18 male. Average age was 60.5 ± 17.3 years. Average testing time of the VR platform was 10 ± 4 minutes. Nine eyes of 5 patients were excluded from visual acuity analysis because they misunderstood the instructions. Of the remaining eyes, 95% limits of agreement for visual acuity ranged from LogMAR -0.53 to 0.43. When using visual acuity worse than 20/40 as a threshold for decreased acuity, the sensitivity for detection of decreased visual acuity was 75% and the specificity was 82%, with a 45% PPV and 94% NPV. For the detection of an EOM deficit, the sensitivity of the VR platform was 100% and the specificity was 75%, with an 11% PPV and 100% NPV. For visual field abnormality by confrontation, the VR platform detected defects with a sensitivity of 50%, specificity of 98%, PPV of 50%, and NPV of 94%. There were no APDs detected by the virtual reality platform or by the clinical exam in our study population.

Conclusions : This pilot study illustrates that the Olleyes VR platform may be useful as a negative screening exam for abnormalities in visual acuity, extraocular motility, and visual field by confrontation. Further work will focus on validating this device in patients with abnormal pathology.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×